Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Anakinra, COVID-19, Cytokine Storm (SOBI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04603742
Recruitment Status : Not yet recruiting
First Posted : October 27, 2020
Last Update Posted : March 25, 2021
Sponsor:
Collaborator:
Swedish Orphan Biovitrum
Information provided by (Responsible Party):
Weill Medical College of Cornell University

Tracking Information
First Submitted Date  ICMJE October 21, 2020
First Posted Date  ICMJE October 27, 2020
Last Update Posted Date March 25, 2021
Estimated Study Start Date  ICMJE July 2021
Estimated Primary Completion Date December 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: October 29, 2020)
Number of subjects alive without having required mechanical ventilation [ Time Frame: 28 days post randomization ]
This will be measured among subjects with COVID-19, features of CSS, and severe respiratory failure (WHO category 4 or 5) who are alive and without having required mechanical ventilation 28 days post randomization.
Original Primary Outcome Measures  ICMJE
 (submitted: October 23, 2020)
Number of subjects who need mechanical ventilation [ Time Frame: 28 days post randomization ]
This will be measured among subjects with severe respiratory failure (WHO category 4 or 5), COVID-19, and features of CSS who receive anakinra compared to those that do not at day 28 after randomization.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: October 29, 2020)
  • 60-day mortality [ Time Frame: 60 days post randomization ]
    Mortality of participants will be compared between those that received anakinra and those that did not.
  • Patient Hospitalization [ Time Frame: 28 days post randomization ]
    The number of days of hospitalization in the anakinra group compared to placebo after randomization up to day 28.
  • Patient Mechanical Ventilation [ Time Frame: 28 days post randomization ]
    The number of days with supplemental oxygen, with noninvasive ventilation or high-flow oxygen at day 28 after randomization in the anakinra group compared to placebo.
Original Secondary Outcome Measures  ICMJE
 (submitted: October 23, 2020)
  • 28-day mortality [ Time Frame: 28 days post randomization ]
    Mortality of participants will be compared between those that received anakinra and those that did not.
  • Patient Hospitalization [ Time Frame: 28 days post randomization ]
    The number of days of hospitalization in the anakinra group compared to placebo after randomization up to day 28.
  • Patient Mechanical Ventilation [ Time Frame: 28 days post randomization ]
    The number of days with supplemental oxygen, with noninvasive ventilation or high-flow oxygen at day 28 after randomization in the anakinra group compared to placebo.
  • 60-day mortality [ Time Frame: 60 days post randomization ]
    Mortality of participants will be compared between those that received anakinra and those that did not.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Anakinra, COVID-19, Cytokine Storm
Official Title  ICMJE Anakinra in Adults With Severe COVID-19 and Features of Cytokine Storm Syndrome: A Randomized, Double-blind, Placebo-controlled Trial
Brief Summary

The clinical syndrome associated with infection of the Coronavirus Disease 2019 (COVID-19) is notable for its variable clinical expression. Infection and transmission of the virus by asymptomatic individuals have been noted and represent one end of the clinical spectrum, while multi-organ failure, particularly pulmonary failure, and death represent the most severe end of the clinical spectrum. In a recent study published from the investigator's institution about the first 393 patients with COVID-19, 77.1% had a fever, a mechanism driven by IL-1. This suggests that there may be an excess release of IL-1 present.

Cytokine storm syndrome (CSS) has been observed in patients with COVID-19 and has been proposed to contribute to the acute pulmonary failure that occurs. In distinct clinical settings, macrophage activation syndrome, elevated levels of pro-inflammatory cytokines, including IL-1, IL-6, and others, as well as elevations in laboratory indicators, including ferritin, CRP, d-dimer, and lymphopenia, have been observed. IL-1 production is induced in response to inflammatory stimuli and mediates various physiologic responses including inflammatory and immunological responses. Anakinra, a recombinant IL-1 receptor antagonist, has shown promise in treating CSS. It inhibits both IL-1-alpha and IL-1-beta. It is an FDA approved medication used in rheumatoid arthritis (RA) and Cryopyrin-Associated Periodic Syndromes (CAPS). Anakinra's ability to inhibit both IL-1 subtypes and short half-life makes it favorable to some experts. In the investigator's case-series, using anakinra in patients with COVID-19 showed promising in preventing the need for mechanical ventilation, and mortality subsequently.

This study will determine the efficacy of anakinra, an interleukin (IL) -1 receptor blocker, in reducing the need for mechanical ventilation and/or 28-day mortality among patients with COVID-19 who have features of CSS and severe respiratory failure. The investigators will test the hypothesis that the proportion of subjects with COVID-19, features of CSS, and severe respiratory failure (World Health Organization (WHO) category 4 or 5) alive and without having required mechanical ventilation at day 28 from randomization will be 18% higher among those that receive anakinra compared to those that receive a placebo. A secondary hypothesis is that the number of subjects alive at 60-days will be higher amongst those who receive anakinra compared to those who receive a placebo.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
This study is a phase II double-blind, placebo-controlled, multicentered trial. Patients in the intervention arm will receive anakinra IV (N=85) 4 times a day for 7 days. The placebo arm will receive normal saline IV (N=85) 4 times a day for 7 days. The investigators will follow up with patients for up to 60 days.
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE
  • Covid19
  • Cytokine Storm
  • Mechanical Ventilation Complication
Intervention  ICMJE
  • Drug: Anakinra
    100 mg of Anakinra will be mixed with 100 mL of 0.9% saline solution for IV administration.
    Other Name: Anakinra IV
  • Drug: 0.9% Saline
    The placebo preparation will consist of a 100 mL of 0.9% saline solution without the addition of anakinra.
    Other Name: Saline IV
Study Arms  ICMJE
  • Experimental: Anakinra IV
    Patients in the intervention arm will receive anakinra IV (N=85) 4 times a day for 7 days. The investigator will follow up with patients for up to 60 days.
    Intervention: Drug: Anakinra
  • Placebo Comparator: Normal Saline IV
    Patients in the placebo arm will receive normal saline IV (N=85) 4 times a day for 7 days. The investigator will follow up with patients for up to 60 days.
    Intervention: Drug: 0.9% Saline
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Not yet recruiting
Estimated Enrollment  ICMJE
 (submitted: March 22, 2021)
170
Original Estimated Enrollment  ICMJE
 (submitted: October 23, 2020)
100
Estimated Study Completion Date  ICMJE February 2022
Estimated Primary Completion Date December 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria

  1. An IRB approved written Informed Consent Form (ICF) is signed and dated by the subject or legal representative.
  2. The subject or legal representative must be considered capable of understanding the study procedures to provide consent for participation according to the judgment of the Investigator.
  3. Molecular diagnosis of SARS-CoV-2 infection within 14 days of screening assessment.
  4. Radiographic evidence of pneumonia by either chest X-ray or computerized tomography (CT) scan of the chest if collected as part of the standard of care.
  5. Age between 18-89 years of age at the screening visit.
  6. The subject must fulfill the inclusion criteria for CSS:

    1. Fever documented ≥ 38 ˚C (from the time of admission to the hospital), or historical fever (patient-reported).

      AND

    2. Respiratory failure defined as:

    i.Requiring supplemental O2 of ≥ 4 L nasal cannula or more to maintain an O2 saturation ≥ 92%, within 36 hours of the requirement for that level of O2.24 (Individuals on continuous positive airway pressure (CPAP) or high flow nasal cannula will be allowed)

    AND

    c. Ferritin > 1000 ng/mL at the time of screening.

  7. Not requiring mechanical ventilation or ECMO at Screening and Baseline Assessments.
  8. ANC must be > 1 x 10^9/L before randomization
  9. Platelet count must be ≥ 50 x 10^9/L before randomization.
  10. Negative pregnancy test before randomization (women of childbearing age only).
  11. GFR ≥ 30 mL/min based on the Modification of Diet in Renal Disease equation.
  12. Subjects participating in studies for convalescent plasma or anticoagulation protocol for COVID-19 will be included as long as these are also open-label.

Exclusion Criteria

  1. The subject is not expected to survive for more than 48 hours from screening, in the opinion of the investigator.
  2. Subjects participating in studies for COVID-19 with immunomodulating drugs, will be excluded. See Section 4.3.1 for drugs or investigational drugs for COVID-19 not allowed in this study.
  3. Subject is currently participating in another study with an investigational drug. Participation in observational studies is allowed.
  4. Known hypersensitivity to anakinra or E. coli derived proteins.
  5. Existence of other evidence that can explain pneumonia including but not limited to: Influenza A virus, Influenza B virus, bacterial pneumonia, fungal pneumonia, or mycobacterial infection.
  6. Known or suspected active TB including those incompletely treated, or known latent TB not adequately treated.

    1. Known or suspected active TB including those incompletely treated.
    2. Exclude patients with known latent TB including those incompletely treated (patient reported).
  7. Known human immunodeficiency virus (HIV) infection.
  8. Culture confirmed active bacterial infection requiring antibiotic therapy.
  9. Subjects who are: do not intubate (DNI) and/or do not resuscitate (DNR) will not be allowed in the study.
  10. Subjects already on mechanical ventilation or on extracorporeal membrane oxygenation (ECMO).
  11. Subjects with Eastern Co-operative Oncology Group (ECOG)/WHO system score ≥ 3 before their hospital admission.
  12. Subjects with past or current lymphoproliferative disorder requiring current medical treatment (e.g., chemotherapy, radiotherapy) for these conditions.
  13. Current or past history of a solid tumor including breast or prostate cancer requiring current medical treatment.
  14. Subjects receiving other immunosuppressants.
  15. Use of the following medications within 6 months of randomization:

    1. Tumor necrosis factor inhibitors
    2. Chronic IL-1 use such as canakinumab or anakinra.
    3. IL-6 inhibitors: Use of any IL-6
    4. Janus kinase inhibitors
    5. Bruton's tyrosine kinase inhibitor
    6. C-C Chemokine receptor type 5
    7. Disease-modifying anti-rheumatic drugs (DMARD), which include cyclosporine, tacrolimus, cyclophosphamide, mycophenolic acid, mycophenolate, penicillamine, azathioprine, methotrexate.
    8. Rituximab and abatacept
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 89 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Iris Y Navarro-Millan, MD, MSPH 646-962-5896 yin9003@med.cornell.edu
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04603742
Other Study ID Numbers  ICMJE 20-07022396
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Weill Medical College of Cornell University
Study Sponsor  ICMJE Weill Medical College of Cornell University
Collaborators  ICMJE Swedish Orphan Biovitrum
Investigators  ICMJE
Principal Investigator: Iris Y Navarro-Millan, MD, MSPH Weill Medical College of Cornell University
PRS Account Weill Medical College of Cornell University
Verification Date March 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP